Korean biosimilar giant Celltrion announced Thursday that its anti-IgE antibody biosimilar Omlyclo has been approved in Europe, after a series of clinical trials with the reference product Novartis' Xolair. Omlyclo, also called by project name CT-P39, received formal product approval from the European Commission on Tuesday, approximately two months after receiving the initial approval recommendation from the C...
Related Keywords
United States , Novarti Xolair , Drug Administration , European Commission On , European Medicines Agency , Committee For Medicinal Products Human , European Commission , Medicinal Products , Human Use , European Medicines ,
comparemela.com © 2020. All Rights Reserved.